IFNG and neoplasm: Moreover, the group of Tavernier have developed Activity-on-Target cytokines (so called Actakines) by fusing inactivated TNF or IFN-γ mutants to a CD13 antibody, leading to selective targeting to the tumor endothelium and complete tumor destruction without side-effects [35].